SCHEMBL7439696

SCHEMBL7439696

CC1Cc2cc(Cl)cc(C(=O)O)c2O1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 7/20 0.51
TDP1 Q9NUW8 1/20 0.44
AKR1B1 P15121 2/20 0.40
AKR1C4 P17516 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
AKR1C1 Q04828 1/20 0.39
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
DYRK1A Q13627 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12036045 0.84 PARP1 (0.48) PARP1
SCHEMBL8939924 0.83 PARP1 (0.52) PARP1TDP1ALDH1A1HPGD
SCHEMBL7334540 0.82 LMNA (0.41) PARP1AKR1B1CYP3A4ALDH1A1TP53
SCHEMBL8939961 0.81 PARP1 (0.76) PARP1TDP1ALDH1A1
SCHEMBL9866564 0.81 PARP1 (0.51) PARP1TDP1AKR1B1ALDH1A1HPGD
SCHEMBL9867744 0.80 PARP1 (0.47) PARP1TDP1
SCHEMBL7126040 0.79 PARP1 (0.49) PARP1TDP1ALDH1A1HPGDHSD17B10
SCHEMBL10806946 0.79 PARP1 (0.49) PARP1TDP1ALDH1A1MAOAMAOB
SCHEMBL10814991 0.78 BRD4 (0.48) PARP1TDP1
SCHEMBL10805151 0.77 PARP1 (0.50) PARP1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5563148-A BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS ELI LILLY AND COMPANY (US) 1996-10-08 US disclosed
EP-0307172-B1 Improvements in or relating to specific 5-HT3 antagonists LILLY CO ELI (US) 1995-10-11 EP disclosed
US-5442078-A Intermediates for specific 5-HT3 antagonists ELI LILLY AND COMPANY (US) 1995-08-15 US disclosed
US-5442077-A Benzo[B]Furancarboxamide derivatives, process for the preparation of same and use thereof for improving hypermotility SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1995-08-15 US disclosed
EP-0640602-A1 Benzo[b]furancarboxamide derivatives, process for their preparation and their use as gastrointestinal mobility-enhancing agents SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1995-03-01 EP disclosed
US-5364863-A Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders ELI LILLY AND COMPANY (US) 1994-11-15 US disclosed
US-5006570-A Dihydrobenzofuran- and chroman-carboxamide derivatives, processes for the preparation thereof and use thereof as neuroleptics LABORATOIRES DELAGRANGE (FR) 1991-04-09 US disclosed
US-4997956-A Analgesics ELI LILLY AND COMPANY (US) 1991-03-05 US disclosed
US-4921982-A 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists ELI LILLY AND COMPANY (US) 1990-05-01 US disclosed
EP-0307172-A2 Improvements in or relating to specific 5-HT3 antagonists ELI LILLY AND COMPANY (US) 1989-03-15 EP disclosed